Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... Each person’s results before and after the study were compared to see the effects ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

After being diagnosed and treated for breast ... Now some doctors are trying GLP-1 drugs — popular medications for weight-loss and Type 2 diabetes — as part of lymphedema therapy and seeing ...

The author supplements GLP-1 medication ... taking a GLP-1. Note: This is not medical advice. Every weight loss journey is different and we suggest consulting your doctor before starting any ...